WO2012135616A1 - Vaccination against advanced glycation end-products - Google Patents
Vaccination against advanced glycation end-products Download PDFInfo
- Publication number
- WO2012135616A1 WO2012135616A1 PCT/US2012/031446 US2012031446W WO2012135616A1 WO 2012135616 A1 WO2012135616 A1 WO 2012135616A1 US 2012031446 W US2012031446 W US 2012031446W WO 2012135616 A1 WO2012135616 A1 WO 2012135616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- age
- vaccine composition
- antigen
- vaccine
- composition
- Prior art date
Links
- 108010005094 Advanced Glycation End Products Proteins 0.000 title claims description 9
- 238000002255 vaccination Methods 0.000 title description 9
- 229960005486 vaccine Drugs 0.000 claims abstract description 57
- 239000000427 antigen Substances 0.000 claims abstract description 36
- 102000036639 antigens Human genes 0.000 claims abstract description 36
- 108091007433 antigens Proteins 0.000 claims abstract description 36
- 239000002671 adjuvant Substances 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 230000003053 immunization Effects 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 10
- 239000003755 preservative agent Substances 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 230000002335 preservative effect Effects 0.000 claims abstract description 8
- 238000002649 immunization Methods 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 25
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 9
- 108010052285 Membrane Proteins Proteins 0.000 claims description 7
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 6
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 6
- 102000007562 Serum Albumin Human genes 0.000 claims description 6
- 108010071390 Serum Albumin Proteins 0.000 claims description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Chemical group 0.000 claims description 6
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 102000018697 Membrane Proteins Human genes 0.000 claims description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 229940031439 squalene Drugs 0.000 claims description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 101710088194 Dehydrogenase Proteins 0.000 claims description 3
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000007859 condensation product Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 229960004279 formaldehyde Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- KHJWSKNOMFJTDN-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KHJWSKNOMFJTDN-UHFFFAOYSA-N 0.000 claims description 2
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Polymers CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 108010078791 Carrier Proteins Proteins 0.000 claims description 2
- 239000004099 Chlortetracycline Substances 0.000 claims description 2
- 238000008416 Ferritin Methods 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 102000004867 Hydro-Lyases Human genes 0.000 claims description 2
- 108090001042 Hydro-Lyases Proteins 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- 102000005890 Spectrin Human genes 0.000 claims description 2
- 108010019965 Spectrin Proteins 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229960005348 antithrombin iii Drugs 0.000 claims description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
- 229960001950 benzethonium chloride Drugs 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004475 chlortetracycline Drugs 0.000 claims description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims description 2
- 235000019365 chlortetracycline Nutrition 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229960003742 phenol Drugs 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 229940127126 plasminogen activator Drugs 0.000 claims description 2
- 229920000024 polymyxin B Polymers 0.000 claims description 2
- 229960005266 polymyxin b Drugs 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 239000005495 thyroid hormone Substances 0.000 claims description 2
- 229940036555 thyroid hormone Drugs 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 102100025255 Haptoglobin Human genes 0.000 claims 1
- 108050005077 Haptoglobin Proteins 0.000 claims 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 102000035118 modified proteins Human genes 0.000 abstract description 2
- 108091005573 modified proteins Proteins 0.000 abstract description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000032942 Vaccine-Preventable disease Diseases 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940124272 protein stabilizer Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 1
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910001593 boehmite Inorganic materials 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- BFSYFTQDGRDJNV-AYHFEMFVSA-N fructosyllysine Chemical compound OC(=O)[C@@H](N)CCCCNCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BFSYFTQDGRDJNV-AYHFEMFVSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- -1 protein stabilizers Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940038774 squalene oil Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Definitions
- AGEs have been associated with several pathological conditions including diabetic complications, inflammation, retinopathy, nephropathy, atherosclerosis, stroke, endothelial cell dysfunction, and neurodegenerative disorders[3].
- AGE-modified erythrocytes have been implicated in the pathogenesis of atherosclerosis, while the absence of AGE-modified erythrocytes has been correlated with reduced atherosclerosis[4].
- Localization of AGEs in atherosclerotic lesions of the aorta in non-diabetic patients has been reported in intima cells, endothelial cells, smooth muscle cells, macrophages and foam cells[5].
- the damage caused by AGE-modified cells may also lead to nephropathy, retinopathy, neuropathy, heart disease, stroke, and peripheral vascular disease[6].
- Vaccines have been widely used, since their introduction by Edward Jenner in the 1770s, to confer immunity against a wide range of diseases, starting from viruses and more recently to other afflictions, like cancer[7].
- Vaccine preparations contain a selected immunogenic agent, such as an antigen (an agent that is the target of an immune response), capable of stimulating immunity to the antigen.
- Typical antigens utilized in vaccines include, for example, viruses, either killed or attenuated, purified viral components, and DNA[8].
- Antigens used in the production of cancer vaccines include, for example, tumor-associated carbohydrate antigens (TACAs), DNA, dendritic cells, whole cells, and viral vectors[9]. Different techniques are employed to produce the desired amount and type of antigen being sought. For example, pathogenic viruses are grown either in eggs or cells[8]. Recombinant DNA technology is often utilized to generate attenuated vaccines[8].
- Immunity is a long-term immune response, either cellular or humoral[7].
- a cellular immune response is activated when an antigen is presented preferably with a co-stimulator to a T-cell, which causes it to differentiate and produces
- Th1 cells stimulate B cells to produce predominantly antibodies of the lgG2A isotype, which activates the complement cascade and binds the Fc receptors of macrophages
- Th2 cells stimulate B cells to produce lgG1 isotype antibodies in mice, lgG4 isotype antibodies in humans, and IgE isotype antibodies[8].
- Professional antigen-presenting cells include dendritic cells, macrophages, and B cells[8].
- a humoral immune response is triggered when a B cell selectively binds to an antigen and begins to proliferate, leading to the production of a clonal population of cells that produce antibodies that specifically recognize that antigen and which may differentiate into antibody-secreting cells, referred to as plasma-cells or memory-B cells[11].
- Antibodies or immunoglobulins are molecules produced by B-cells that bind the specific antigen[8].
- the antigen-antibody complex also triggers several responses, either cell-mediated, for example by natural killers (NK) or macrophages, or serum-mediated, for example by activating the complement system, a complex of several serum proteins that act sequentially in a cascade that result in the lysis of the target cell[8].
- Immunological adjuvants are the following:
- Adjuvants function by attracting macrophages to the immunogenic agent and then presenting the agent to the regional lymph nodes to initiate an effective antigenic response. Adjuvants may also act as carriers themselves for the immunogenic agent. Adjuvants may induce an inflammatory response, which may play an important role in initiating the immune response[8].
- Adjuvants include: mineral compounds such as aluminum salts, oil emulsions, bacterial products, liposomes, immunostimulating complexes, and squalene.
- the present invention is a vaccine composition, for
- immunizing a human patient comprising (a) an AGE antigen, (b) an adjuvant, (c) a preservative, and (d) optionally, an excipient.
- the present invention is a method of treating
- Atherosclerosis comprising immunizing a human patient in need thereof against AGE-modified proteins.
- the present invention is a method of immunizing a human patient against AGE-modified proteins, comprising administering a vaccine composition, in an amount effective to cause immunization against AGE-modified proteins.
- the present invention makes use of the discovery that enhanced clearance of cells containing AGE-modified proteins (AGE-modified cells), such as erythrocytes, is beneficial in reducing cardiovascular disease, especially when present as a complication of diabetes, or the pre-diabetic condition referred to as "Syndrome-X". Elevated blood glucose concentrations lead to modifications of protein side chains in cells, including circulating erythrocytes and other cell types. Non-enzymatic glycation of membrane proteins results in the formation of AGE-modified cells, which cause reduced cell deformability that is associated with the formation of atherosclerotic lesions.
- AGE-modified cells such as erythrocytes
- Vaccination against AGE-modified proteins produces the desired result of controlling the production of AGE-modified proteins in a subject in need thereof.
- the continuous and virtually ubiquitous surveillance exercised by the immune system in the body in response to a vaccination allows maintaining low levels of AGE-modified cells in the body.
- vaccination against AGE-modified proteins, particularly AGE-modified proteins of erythrocytes may be used to treat
- AGE-modified proteins are also a marker of partially- and non-functional cells. Vaccination against AGE-modified proteins can also help remove or kill these partially- and non-functional cells, to enhance regeneration by allowing functional cells to replace them. See, for example, WO 2009/1 341 1 to Gruber (26 Nov.
- a vaccine against AGE-modified proteins can be used in a method for promoting tissue or organ regeneration in a subject by killing partially-functional or non-functional cells.
- the vaccine can also have cosmetic effects, for example reducing aging or the appearance of aging, of the skin and/or hair. These methods are particularly applicable to diabetic persons, where high blood glucose levels enhance the presence of AGE-modified proteins.
- Vaccines against AGE-modified proteins contain an AGE antigen, an adjuvant, a preservative and optional excipients.
- AGE antigens are AGE-modified proteins, and mixtures thereof, which can elicit an immune response in humans, preferably when administered in the presence of one or more adjuvants.
- Examples include AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-l and II, AGE-hemoglobin, AGE-Na + /K + -ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, ⁇ - ⁇ - ⁇ -acetyl hexominase, AGE-apo
- These proteins may be produced by isolation of the protein from natural sources or recombinantly, followed by AGE modification, for example by incubation in a 0.1-3 M solution of glucose, glucose-6-phosphate, fructose or ribose, for 10-100 days, where the solution is buffered with a phosphate buffer at a pH of 6-8. Fragments and digestates of the proteins may also be used, followed by AGE modification, as long as the fragments and digestates contain reducing amino acids, so that a Schiff base is formed and the Amadori reaction can take place to form the corresponding ketoamine.
- AGE-modified cells such as AGE- modified erythrocytes, whole, lysed, or partially digested, may also be used. Further details of some of these AGE-modified proteins and their preparation are described in U.S. Patent No. 5,702,704 to Bucala (issued December 30, 1997) (hereby incorporated by reference).
- the AGE-modified proteins which are targets of the vaccine are AGE-modified proteins of cell, and exclude non-cellular modified proteins, for example exclude AGE-modified albumin and/or AGE-modified collagen.
- the AGE antigen is a condensation product advanced glycation end-product comprising a lysine component, an argine component and a reducing sugar component, as described in U.S. Patent No. 6,380,165 to Al-Abed et al. (issued April 30, 2002) (hereby incorporated by reference).
- Examples include an advanced glycation end-product comprising a condensation product of a lysyl component, an arginyl component and a reducing sugar component, wherein the arginyl component and the reducing sugar component form a monocyclic substituted imidazole; for example a compound according to formula I:
- a lysyl component is indicated by the box labeled "K”; an arginyl component is indicated by the boxy labeled “R”; and a reducing sugar component is not boxed; and wherein Ri and R 4 are independently H or an amide bond to an amino acid residue or a peptide chain; R 2 and R 3 are, independently, OH or an amide bond to an amino acid residue or a peptide chain; R 5 is H, CH 2 OH or CHOHCH 2 OH; and wherein if more than one of R-i , R 2 , R 3 or R 4 is an amide bond, then the lysyl "K” component and the arginyl "R” component may be amino acid residues of the same or a different peptide chain.
- AGE-RNAse AGE-RNAse
- AGE-hemoglobin such as AGE-human hemoglobin
- AGE-albumin such as AGE-bovine serum albumin and AGE-human serum albumin
- AGE-LDL AGE-low density lipoprotein
- AGE- collagen IV AGE- collagen IV
- the vaccine used to vaccinate a human contains from 1 microgram to 100 milligrams of at least one AGE antigen, including 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 400, 800 or 1000 micrograms, or 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80 or 90 milligrams.
- the amount used for a single injection corresponds to a unit dosage.
- Aluminum compounds are the most widely used adjuvants in human and veterinary vaccines. These aluminum compounds include aluminum salts such as aluminum phosphate (AIP0 4 ) and aluminum hydroxide (AI(OH) 3 ) compounds, typically in the form of gels, and are generically referred to in the field of vaccine immunological adjuvants as "alum".
- Aluminum hydroxide is a poorly crystalline aluminum oxyhydroxide having the structure of the mineral boehmite.
- Aluminum phosphate is an amorphous aluminum hydroxyphosphate.
- Negatively charged species can absorb onto aluminum hydroxide gels at neutral pH
- positively charged species can absorb onto aluminum phosphate gels at neutral pH. It is believed that these aluminum compounds provide a depot of antigen at the site of administration (for example, injection), thereby providing a gradual and continuous release of antigen to stimulate antibody production. Aluminum compounds tend to more effectively stimulate a cellular response mediated by Th2, rather than Th1 cells[12].
- Emulsion adjuvants include water-in-oil emulsions (for example, Freund's adjuvants, such as killed mycobacteria in oil emulsion) and oil-in-water emulsions (for example, F-59).
- Emulsion adjuvants include an immunogenic component, for example squalene (MF-59) or mannide oleate (Incomplete Freund's Adjuvants), which can induce an elevated humoral response, increased T cell proliferation, cytotoxic lymphocytes, and cell-mediated immunity.
- Liposomal or vesicular adjuvants include paucilamellar lipid vesicles
- Paucilamellar vesicles can be prepared by mixing, under high pressure or shear conditions, a lipid phase comprising a non- phospholipid material (for example, an amphiphile surfactant; see U.S. Pat. Nos.
- a sterol optionally a sterol, and any water-immiscible oily material to be encapsulated in the vesicles (for example, an oil such as squalene oil and an oil-soluble or oil-suspended antigen); and an aqueous phase such as water, saline, buffer or any other aqueous solution used to hydrate the lipids.
- an oil such as squalene oil and an oil-soluble or oil-suspended antigen
- aqueous phase such as water, saline, buffer or any other aqueous solution used to hydrate the lipids.
- Liposomal or vesicular adjuvants are believed to promote contact of the antigen with immune cells, for example by fusion of the vesicle to the immune cell membrane, and preferentially stimulate the Th1 sub-population of T-helper cells.
- BCG Guerin
- CpG motifs unmethylated CpG dinucleotides
- Additional adjuvants are described in U.S. Patent Application Publication, Pub. No. US 2010/0226932 (Sept. 9, 2010), and Jiang, ZH er a/[14].
- Preferable adjuvants include Freund's complete adjuvant and Freund's incomplete adjuvant.
- One or more preservatives such as antioxidants, antibacterial and/or antibacterial agents
- antimicrobial agents as well as combinations thereof, are also included in the vaccine.
- examples include benzethonium chloride, ethylenediamine-tetraacetic acid sodium (EDTA), thimerosal, phenol, 2-phenoxyethanol, formaldehyde and formalin; antibacterial agents such as amphotericin B, chlortetracycline, gentamicin, neomycin, polymyxin B and streptomycin; antimicrobial surfactants such as polyoxyethylene-9, 10-nonyl phenol (Triton N-101 , octoxynol-9), sodium
- excipients such as stabilizers, thickening agents, toxin detoxifiers, diluents, pH adjusters, tonicity adjustors, surfactants, antifoaming agents, protein stabilizers, dyes and solvents.
- excipients include hydrochloric acid, phosphate buffers, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, potassium chloride, potassium chloride, sodium chloride,
- polydimethylsilozone brilliant green, phenol red (phenolsulfon-phthalein), glycine, glycerin, sorbitol, histidine, monosodium glutamate, potassium glutamate, sucrose, urea, lactose, gelatin, sorbitol, polysorbate 20, polysorbate 80 and glutaraldehyde.
- the vaccine is provided in unit dosage form, or multidosage form, such as 2-100, or 2-10 doses in a packed, sterilized, ready-to-inject form.
- the unit dosages may be provided in a vial with a septum, or in a syringe with or without a needle.
- the vaccine may be administered intravenously, subdermally, or intraperitoneally.
- the vaccine may be administered one or more times, such as 1 to 10 times, including 2, 3, 4, 5, 6, 7, 8 or 9 times, over a period of time ranging from 1 week to 1 year, 2-10 weeks or 2-10 months.
- booster vaccinations may be desirable, over the course of 1 year to 20 years, including 2, 5, 10 and 15 years.
- Example 1 (Prophetic): AGE-RNAse containing vaccine in a human subject.
- AGE-RNAse is prepared by incubating RNAse in a phosphate buffer solution containing 0.1 -3M glucose, glucose-6-phosphate, fructose, or ribose for 10-100 days. The AGE-RNAse solution is dialyzed and the protein content is measured. Virella et a/.[25]. Aluminum hydroxide or aluminum phosphate, as an adjuvant, is added to 100 microgram of the AGE-RNAse. Formaldehyde or formalin is added as a preservative to the preparation. Moreover, ascorbic acid is added as an antioxidant.
- the vaccine also includes other excipients: phosphate buffer to adjust the pH, and glycine as a protein stabilizer. The composition is injected into a human subject subcutaneously and the titer of AGE-RNAse antibody is determined by ELISA one month after the inoculation. Ameli et al. [26].
- Example 2 Injection regimen for an AGE-RNAse containing vaccine in a human subject.
- Example 3 An AGE-hemoglobin containing vaccine in a human subject.
- AGE-hemoglobin is prepared by incubating human hemoglobin in a phosphate buffer solution containing 0.1-3M glucose, glucose-6-phosphate, fructose, or ribose for 10-100 days. The AGE-hemoglobin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 1 , except AGE-hemoglobin is substituted for AGE-RNAse. Administration is carried out as in Example 1 , or as in Example 2.
- Example 4 (Prophetic): AGE-human serum albumin containing vaccine in a human subject.
- AGE-human serum albumin is prepared by incubating human serum albumin in a phosphate buffer solution containing 0.1-3M glucose, glucose-6-phosphate, fructose, or ribose for 10-100 days. The AGE-human serum albumin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 1 , except AGE-human serum albumin is substituted for AGE-RNAse. Administration is carried out as in Example 1 , or as in Example 2.
Abstract
A vaccine composition, for immunizing a human patient, comprises an AGE antigen, an adjuvant, a preservative, and optionally an excipient. A method of immunizing a human patient against AGE-modified proteins comprises administering the vaccine composition, in an amount effective to cause immunization against AGE- modified proteins. Immunizing a human patient against AGE-modified proteins may be used to treat atherosclerosis.
Description
VACCINATION AGAINST ADVANCED GLYCATION END-PRODUCTS
CROSS REFERENCE TO RELATED APPLICATION
[01] This application claims the benefit of provisional application no. 61/470,167 entitled "VACCINATION AGAINST ADVANCED GLYCATION END-PRODUCTS" filed 31 March 2011 , attorney docket no. SIW01-004-PRO, the entire contents of which are hereby incorporated by reference, except where inconsistent with the present application.
BACKGROUND
[02] Advanced glycation end-products (AGEs; also referred to AGE-modified
proteins) arise from a non-enzymatic reaction of sugars with protein side-chains in aging cells[1]. Hyperglycemia, caused by diabetes mellitus (DM), and oxidative stress promote this post-translational modification of membrane proteins[2]. AGEs have been associated with several pathological conditions including diabetic complications, inflammation, retinopathy, nephropathy, atherosclerosis, stroke, endothelial cell dysfunction, and neurodegenerative disorders[3].
[03] AGE-modified erythrocytes have been implicated in the pathogenesis of atherosclerosis, while the absence of AGE-modified erythrocytes has been correlated with reduced atherosclerosis[4]. Localization of AGEs in atherosclerotic lesions of the aorta in non-diabetic patients has been reported in intima cells, endothelial cells, smooth muscle cells, macrophages and foam cells[5]. The damage caused by AGE-modified cells may also lead to nephropathy, retinopathy, neuropathy, heart disease, stroke, and peripheral vascular disease[6].
[04] Vaccines have been widely used, since their introduction by Edward Jenner in the 1770s, to confer immunity against a wide range of diseases, starting from viruses and more recently to other afflictions, like cancer[7]. Vaccine preparations contain a selected immunogenic agent, such as an antigen (an agent that is the target of an immune response), capable of stimulating immunity to the antigen. Typical antigens utilized in vaccines include, for example, viruses, either killed or attenuated, purified
viral components, and DNA[8]. Antigens used in the production of cancer vaccines include, for example, tumor-associated carbohydrate antigens (TACAs), DNA, dendritic cells, whole cells, and viral vectors[9]. Different techniques are employed to produce the desired amount and type of antigen being sought. For example, pathogenic viruses are grown either in eggs or cells[8]. Recombinant DNA technology is often utilized to generate attenuated vaccines[8].
[05] Immunity is a long-term immune response, either cellular or humoral[7]. A cellular immune response is activated when an antigen is presented preferably with a co-stimulator to a T-cell, which causes it to differentiate and produces
cytokines[10]. The cells involved in the generation of the cellular immune response are two classes of T-helper (Th) cells, Th1 and Th2[8]. Th1 cells stimulate B cells to produce predominantly antibodies of the lgG2A isotype, which activates the complement cascade and binds the Fc receptors of macrophages, while Th2 cells stimulate B cells to produce lgG1 isotype antibodies in mice, lgG4 isotype antibodies in humans, and IgE isotype antibodies[8]. Professional antigen-presenting cells include dendritic cells, macrophages, and B cells[8].
[06] A humoral immune response is triggered when a B cell selectively binds to an antigen and begins to proliferate, leading to the production of a clonal population of cells that produce antibodies that specifically recognize that antigen and which may differentiate into antibody-secreting cells, referred to as plasma-cells or memory-B cells[11]. Antibodies or immunoglobulins, are molecules produced by B-cells that bind the specific antigen[8]. The antigen-antibody complex also triggers several responses, either cell-mediated, for example by natural killers (NK) or macrophages, or serum-mediated, for example by activating the complement system, a complex of several serum proteins that act sequentially in a cascade that result in the lysis of the target cell[8].
[07] Immunological adjuvants (also referred to simply as "adjuvants") are the
component(s) of a vaccine which augment the immune response to the
immunogenic agent. Adjuvants function by attracting macrophages to the immunogenic agent and then presenting the agent to the regional lymph nodes to
initiate an effective antigenic response. Adjuvants may also act as carriers themselves for the immunogenic agent. Adjuvants may induce an inflammatory response, which may play an important role in initiating the immune response[8]. Adjuvants include: mineral compounds such as aluminum salts, oil emulsions, bacterial products, liposomes, immunostimulating complexes, and squalene.
[08] Other components of vaccines include pharmaceutically acceptable
excipients, preservatives, diluents, and pH adjusters. A variety of these components of vaccines, as well as adjuvants, are described in
www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table- 1.pdf, www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient- table-2.pdf, and Vogel FR, er a/[15].
SUMMARY
[09] In a first aspect, the present invention is a vaccine composition, for
immunizing a human patient, comprising (a) an AGE antigen, (b) an adjuvant, (c) a preservative, and (d) optionally, an excipient.
[10] In a second aspect, the present invention is a method of treating
atherosclerosis, comprising immunizing a human patient in need thereof against AGE-modified proteins.
[1 1] In a third aspect, the present invention is a method of immunizing a human patient against AGE-modified proteins, comprising administering a vaccine composition, in an amount effective to cause immunization against AGE-modified proteins.
DETAILED DESCRIPTION
[12] The present invention makes use of the discovery that enhanced clearance of cells containing AGE-modified proteins (AGE-modified cells), such as erythrocytes, is beneficial in reducing cardiovascular disease, especially when present as a complication of diabetes, or the pre-diabetic condition referred to as "Syndrome-X".
Elevated blood glucose concentrations lead to modifications of protein side chains in cells, including circulating erythrocytes and other cell types. Non-enzymatic glycation of membrane proteins results in the formation of AGE-modified cells, which cause reduced cell deformability that is associated with the formation of atherosclerotic lesions. Vaccination against AGE-modified proteins produces the desired result of controlling the production of AGE-modified proteins in a subject in need thereof. The continuous and virtually ubiquitous surveillance exercised by the immune system in the body in response to a vaccination, allows maintaining low levels of AGE-modified cells in the body. In particular, vaccination against AGE-modified proteins, particularly AGE-modified proteins of erythrocytes, may be used to treat
atherosclerosis.
AGE-modified proteins are also a marker of partially- and non-functional cells. Vaccination against AGE-modified proteins can also help remove or kill these partially- and non-functional cells, to enhance regeneration by allowing functional cells to replace them. See, for example, WO 2009/1 341 1 to Gruber (26 Nov.
2009). A vaccine against AGE-modified proteins can be used in a method for promoting tissue or organ regeneration in a subject by killing partially-functional or non-functional cells. The vaccine can also have cosmetic effects, for example reducing aging or the appearance of aging, of the skin and/or hair. These methods are particularly applicable to diabetic persons, where high blood glucose levels enhance the presence of AGE-modified proteins.
Vaccines against AGE-modified proteins contain an AGE antigen, an adjuvant, a preservative and optional excipients. AGE antigens are AGE-modified proteins, and mixtures thereof, which can elicit an immune response in humans, preferably when administered in the presence of one or more adjuvants. Examples include AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-l and II, AGE-hemoglobin, AGE-Na+/K+-ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell
Glu transport protein, ΑΘΕ-β-Ν-acetyl hexominase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE- alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE- 2-microglobulin, AGE-sorbitol dehydrogenase, AGE-c - antitrypsin, AGE-carbonate dehydratase, AGE-RNAse, AGE-low density lipoprotein, AGE-hexokinase and AGE-apo C-l. These proteins may be produced by isolation of the protein from natural sources or recombinantly, followed by AGE modification, for example by incubation in a 0.1-3 M solution of glucose, glucose-6-phosphate, fructose or ribose, for 10-100 days, where the solution is buffered with a phosphate buffer at a pH of 6-8. Fragments and digestates of the proteins may also be used, followed by AGE modification, as long as the fragments and digestates contain reducing amino acids, so that a Schiff base is formed and the Amadori reaction can take place to form the corresponding ketoamine. AGE-modified cells, such as AGE- modified erythrocytes, whole, lysed, or partially digested, may also be used. Further details of some of these AGE-modified proteins and their preparation are described in U.S. Patent No. 5,702,704 to Bucala (issued December 30, 1997) (hereby incorporated by reference).
Preferably, the AGE-modified proteins which are targets of the vaccine are AGE-modified proteins of cell, and exclude non-cellular modified proteins, for example exclude AGE-modified albumin and/or AGE-modified collagen. Preferably, the AGE antigen is a condensation product advanced glycation end-product comprising a lysine component, an argine component and a reducing sugar component, as described in U.S. Patent No. 6,380,165 to Al-Abed et al. (issued April 30, 2002) (hereby incorporated by reference). Examples include an advanced glycation end-product comprising a condensation product of a lysyl component, an arginyl component and a reducing sugar component, wherein the arginyl component and the reducing sugar component form a monocyclic substituted imidazole; for example a compound according to formula I:
wherein a lysyl component is indicated by the box labeled "K"; an arginyl component is indicated by the boxy labeled "R"; and a reducing sugar component is not boxed; and wherein Ri and R4 are independently H or an amide bond to an amino acid residue or a peptide chain; R2 and R3 are, independently, OH or an amide bond to an amino acid residue or a peptide chain; R5 is H, CH2OH or CHOHCH2OH; and wherein if more than one of R-i , R2, R3 or R4 is an amide bond, then the lysyl "K" component and the arginyl "R" component may be amino acid residues of the same or a different peptide chain.
Other preferred AGE antigens are AGE-RNAse, AGE-hemoglobin such as AGE-human hemoglobin, AGE-albumin such as AGE-bovine serum albumin and AGE-human serum albumin, AGE-low density lipoprotein (AGE-LDL) and AGE- collagen IV, such as those described in U.S. Patent No. 5,702,704 to Bucala (issued December 30, 1997).
Preferably, the vaccine used to vaccinate a human contains from 1 microgram to 100 milligrams of at least one AGE antigen, including 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 400, 800 or 1000 micrograms, or 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80 or 90 milligrams. The amount used for a single injection corresponds to a unit dosage.
Adjuvants included: mineral compounds such as aluminum salts, oil emulsions, bacterial products, liposomes, immunostimulating complexes, and squalene. Aluminum compounds are the most widely used adjuvants in human and veterinary vaccines. These aluminum compounds include aluminum salts such as
aluminum phosphate (AIP04) and aluminum hydroxide (AI(OH)3) compounds, typically in the form of gels, and are generically referred to in the field of vaccine immunological adjuvants as "alum". Aluminum hydroxide is a poorly crystalline aluminum oxyhydroxide having the structure of the mineral boehmite. Aluminum phosphate is an amorphous aluminum hydroxyphosphate. Negatively charged species (for example, negatively charged antigens) can absorb onto aluminum hydroxide gels at neutral pH, whereas positively charged species (for example, positively charged antigens) can absorb onto aluminum phosphate gels at neutral pH. It is believed that these aluminum compounds provide a depot of antigen at the site of administration (for example, injection), thereby providing a gradual and continuous release of antigen to stimulate antibody production. Aluminum compounds tend to more effectively stimulate a cellular response mediated by Th2, rather than Th1 cells[12].
[19] Emulsion adjuvants include water-in-oil emulsions (for example, Freund's adjuvants, such as killed mycobacteria in oil emulsion) and oil-in-water emulsions (for example, F-59). Emulsion adjuvants include an immunogenic component, for example squalene (MF-59) or mannide oleate (Incomplete Freund's Adjuvants), which can induce an elevated humoral response, increased T cell proliferation, cytotoxic lymphocytes, and cell-mediated immunity.
[20] Liposomal or vesicular adjuvants (including paucilamellar lipid vesicles) have lipophilic bilayer domains and an aqueous milieu which can be used to encapsulate and transport a variety of materials, for example an antigen. Paucilamellar vesicles (for example, those described in U.S. Pat. No. 6,387,373) can be prepared by mixing, under high pressure or shear conditions, a lipid phase comprising a non- phospholipid material (for example, an amphiphile surfactant; see U.S. Pat. Nos. 4,217,344; 4,917,951 ; and 4,911 ,928), optionally a sterol, and any water-immiscible oily material to be encapsulated in the vesicles (for example, an oil such as squalene oil and an oil-soluble or oil-suspended antigen); and an aqueous phase such as water, saline, buffer or any other aqueous solution used to hydrate the lipids.
Liposomal or vesicular adjuvants are believed to promote contact of the antigen with
immune cells, for example by fusion of the vesicle to the immune cell membrane, and preferentially stimulate the Th1 sub-population of T-helper cells.
[21] Other types of adjuvants include Mycobacterium bovis bacillus Calmette-
Guerin (BCG), quill-saponin, unmethylated CpG dinucleotides (CpG motifs)[13]. Additional adjuvants are described in U.S. Patent Application Publication, Pub. No. US 2010/0226932 (Sept. 9, 2010), and Jiang, ZH er a/[14]. Preferable adjuvants include Freund's complete adjuvant and Freund's incomplete adjuvant.
[22] One or more preservatives, such as antioxidants, antibacterial and
antimicrobial agents, as well as combinations thereof, are also included in the vaccine. Examples include benzethonium chloride, ethylenediamine-tetraacetic acid sodium (EDTA), thimerosal, phenol, 2-phenoxyethanol, formaldehyde and formalin; antibacterial agents such as amphotericin B, chlortetracycline, gentamicin, neomycin, polymyxin B and streptomycin; antimicrobial surfactants such as polyoxyethylene-9, 10-nonyl phenol (Triton N-101 , octoxynol-9), sodium
deoxycholate and polyoxyethylated octyl phenol (Triton X-I00).
[23] Other components of vaccines include pharmaceutically acceptable
excipients, such as stabilizers, thickening agents, toxin detoxifiers, diluents, pH adjusters, tonicity adjustors, surfactants, antifoaming agents, protein stabilizers, dyes and solvents. Examples of such excipients include hydrochloric acid, phosphate buffers, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, potassium chloride, potassium chloride, sodium chloride,
polydimethylsilozone, brilliant green, phenol red (phenolsulfon-phthalein), glycine, glycerin, sorbitol, histidine, monosodium glutamate, potassium glutamate, sucrose, urea, lactose, gelatin, sorbitol, polysorbate 20, polysorbate 80 and glutaraldehyde. A variety of these components of vaccines, as well as adjuvants, are described in www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table- 1.pdf, www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient- table-2.pdf, and Vogel FR, et a/[15].
Preferably, the vaccine is provided in unit dosage form, or multidosage form, such as 2-100, or 2-10 doses in a packed, sterilized, ready-to-inject form. The unit dosages may be provided in a vial with a septum, or in a syringe with or without a needle. The vaccine may be administered intravenously, subdermally, or intraperitoneally. For vaccination, preferably the vaccine may be administered one or more times, such as 1 to 10 times, including 2, 3, 4, 5, 6, 7, 8 or 9 times, over a period of time ranging from 1 week to 1 year, 2-10 weeks or 2-10 months.
Furthermore, booster vaccinations may be desirable, over the course of 1 year to 20 years, including 2, 5, 10 and 15 years.
EXAMPLES
Example 1 (Prophetic): AGE-RNAse containing vaccine in a human subject.
AGE-RNAse is prepared by incubating RNAse in a phosphate buffer solution containing 0.1 -3M glucose, glucose-6-phosphate, fructose, or ribose for 10-100 days. The AGE-RNAse solution is dialyzed and the protein content is measured. Virella et a/.[25]. Aluminum hydroxide or aluminum phosphate, as an adjuvant, is added to 100 microgram of the AGE-RNAse. Formaldehyde or formalin is added as a preservative to the preparation. Moreover, ascorbic acid is added as an antioxidant. The vaccine also includes other excipients: phosphate buffer to adjust the pH, and glycine as a protein stabilizer. The composition is injected into a human subject subcutaneously and the titer of AGE-RNAse antibody is determined by ELISA one month after the inoculation. Ameli et al. [26].
Example 2 (Prophetic): Injection regimen for an AGE-RNAse containing vaccine in a human subject.
The same vaccine as in Example 1 is injected into a human subject. The titer of AGE-RNAse is determined by ELISA after two weeks. Additional injections are performed after three weeks and six weeks, respectively. Further titer determination is performed two weeks after each injection.
Example 3 (Prophetic): An AGE-hemoglobin containing vaccine in a human subject.
AGE-hemoglobin is prepared by incubating human hemoglobin in a phosphate buffer solution containing 0.1-3M glucose, glucose-6-phosphate, fructose, or ribose for 10-100 days. The AGE-hemoglobin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 1 , except AGE-hemoglobin is substituted for AGE-RNAse. Administration is carried out as in Example 1 , or as in Example 2.
Example 4 (Prophetic): AGE-human serum albumin containing vaccine in a human subject.
AGE-human serum albumin is prepared by incubating human serum albumin in a phosphate buffer solution containing 0.1-3M glucose, glucose-6-phosphate, fructose, or ribose for 10-100 days. The AGE-human serum albumin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 1 , except AGE-human serum albumin is substituted for AGE-RNAse. Administration is carried out as in Example 1 , or as in Example 2.
[34] REFERENCES
[35] 1. Ando K, et al., "Membrane Proteins of Human Erythrocytes Are Modified by
Advanced Glycation End Products During Aging in the Circulation," Biochemical and Biophysical Research Communications, Vol. 258, 123-27 (1999).
[36] 2. Lindsey JB, et al,, "Receptor For Advanced Glycation End-Products
(RAGE) and soluble RAGE (sRAGE): Cardiovascular Implications," Diabetes Vascular Disease Research, Vol. 6(1), 7-14, (2009).
[37] 3. Bierhaus A, "AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept," Cardiovasc Res, Vol. 37(3), 586-600 (1998).
[38] 4. Jandeleit-Dahm K, et al., "The AGE/RAGE Axis in Diabetes-Accelerated
Atherosclerosis," Clinical and Experimental Pharmacology and Physiology, Vol. 35, 329-334 (2008).
[39] 5. Sakata N. et al., "Immunohistochemical Localization of Different Epitopes of
Advanced Glycation End Products in Human Atherosclerotic Lesions,"
Atherosclerosis, 141 , 61-75 (1998).
[40] 6. Karachalias N. et al., "Accumulation of Fructosyl-Lysine and Advanced
Glycation End Products in the Kidney, Retina and Peripheral Nerve of
Streptozotocin-lnduced Diabetic Rats." Biochemical Society Transactions, 31 , 1423- 25 (2003).
[41] 7. Murphy JF, "Trends in cancer immunotherapy," Clin Med Insigths Oncol,
Vol. 14(4), 67-80 (2010).
[42] 8. Flint SJ et al. , "Principles of Virology," ASM Press (2000).
[43] 9. Buskas T et al., immunotherapy for Cancer: Synthetic Carbohydrate-based
Vaccines," Chem Commun, Vol. 28(36), 5335-349 (2009).
[44] 10. Beier KC, "Master Switches of T-cell Differentiation," Eur Resp J, Vol. 29,
804-12 (2007).
[45] 1 1 . Schmidlin H, "New Insights in the Regulation of Human B Cell
Differentiation," Trends Immunol, Vol. 30(6), 277-85 (2009).
[46] 12. Coler R et al. , "Development and Characterization of Synthetic
Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant," PLoS ONE, Vol. 6(1): e16333 (201 1 ).
[47] 13. Cheadle EJ, "Bugs as Drugs for Cancer," Immunology, Vol. 107, 10-19
(2002).
[48] 14. Jiang, ZH et al. "Synthetic vaccines: the role of adjuvants in immune targeting," Curr Med Chem 10(15): 1423-39 (2003).
[49] 15. Vogel FR, et al. "A compendium of vaccine adjuvants and excipients,"
Pharm Biotechnol 6: 141-228 (1995).
[50] 16. U.S. Patent No. 5,702,704 to Bucala (issued December 30, 1997).
[51] 17. U.S. Patent No. 6,380, 165 to Al-Abed et al. (issued April 30, 2002).
[52] 18. U.S. Patent No. 6,387,373 to Wright et al. (issued May 14, 2002).
[53] 19. U.S. Patent No. 4,217,344 to Vanlerberghe et al. (issued August 12,
1980).
[54] 20. U.S. Patent No. 4,917,951 to Wallach (issued April 17, 1990).
[55] 21. U.S. Patent No. 4,911 ,928 to Wallach (issued March 27, 1990).
[56] 22. U.S. Application Publication, Pub. No. US 2010/226932 to Smith et al.
(September 9, 2010).
[57] 23. www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/ excipient-table-1.pdf (The Pink Book, Epidemiology and Prevention of Vaccine Preventable Diseases, 1 1th Ed., May 2009).
[58] 24. www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/
excipient-table-2.pdf (The Pink Book, Epidemiology and Prevention of Vaccine Preventable Diseases, 1 1th Ed., May 2009).
[59] 25. Virella G et al. , "Autoimmune Response to Advanced Glycosylation End-
Products of Human LDL," Journal of Lipid Res, Vol. 44, 487-493 (2003).
[60] 26. Ameli S et al. , "Effect of Immunization With Homologous LDL and
Oxidized LDL on Early Atherosclerosis in Hypercholesterolemic Rabbits,"
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 16, 1074 (1996).
[61] 27. International Application, Publication No. WO 2009/14341 1 to Gruber (26
Nov. 2009).
Claims
1. A vaccine composition, for immunizing a human patient, comprising:
(a) an AGE antigen,
(b) an adjuvant,
(c) a preservative, and
(d) optionally, an excipient.
2. The vaccine composition of claim 1 , wherein the AGE antigen is an AGE-modified protein selected from the group consisting of AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE- copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A- I and II, AGE-hemoglobin, AGE-Na7K+-ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-β-Ν- acetyl hexominase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE- haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE- 2- microglobulin, AGE-sorbitol dehydrogenase, AGE-arantitrypsin, AGE-carbonate dehydratase, AGE-RNAse, AGE-low density lipoprotein, AGE-hexokinase, AGE-apo C-l, and mixtures thereof.
3. The vaccine composition of any of the preceding claims, wherein the AGE antigen is an AGE-modified protein selected from the group consisting of AGE- RNAse, AGE-human hemoglobin, AGE-human serum albumin, AGE-low density lipoprotein, AGE-collagen IV, and mixtures thereof.
4. The vaccine composition of any of the preceding claims, wherein the AGE antigen is a condensation product advanced glycation end-product comprising a lysine component, an argine component and a reducing sugar component.
5. The vaccine composition of any of the preceding claims, wherein the AGE antigen is a compound of formula I:
wherein the lysyl component is indicated by the box labeled "K"; an arginyl component is indicated by the boxy labeled "R"; and a reducing sugar component is not boxed; and wherein R1 and R4 are independently H or an amide bond to an amino acid residue or a peptide chain; R2 and R3 are, independently, OH or an amide bond to an amino acid residue or a peptide chain; R5 is H, CH20H or CHOHCH20H; and wherein if more than one of R1 , R2, R3 or R4 is an amide bond, then the lysyl "K" component and the arginyl "R" component may be amino acid residues of the same or a different peptide chain.
6. The vaccine composition of any of the preceding claims, wherein the adjuvant comprises at least one member selected from the group consisting of aluminum phosphate, aluminum hydroxide, a water-in-oil emulsions, an oil-in-water emulsions, squalene, mannide oleate, a liposom, a vesicul, a paucilamellar vesicle, Mycobacterium bovis bacillus Calmette-Guerin, quill-saponin, unmethylated CpG dinucleotides, Freund's complete adjuvant and Freund's incomplete adjuvant.
7. The vaccine composition of any of the preceding claims, wherein the adjuvant comprises at least one member selected from the group consisting of aluminum phosphate, aluminum hydroxide, Freund's complete adjuvant and
Freund's incomplete adjuvant.
8. The vaccine composition of any of the preceding claims, wherein the preservative comprises at least one member selected from the group consisting of an antioxidant, an antibacterial agent and an antimicrobial agent.
9. The vaccine composition of any of the preceding claims, wherein the preservative comprises at least one member selected from the group consisting of benzethonium chloride, ethylenediamine-tetraacetic acid sodium, thimerosal, phenol, 2-phenoxyethanol, formaldehyde, formalin, amphotericin B, chlortetracycline, gentamicin, neomycin, polymyxin B, streptomycin, polyoxyethylene-9, 10-nonyl phenol, sodium deoxycholate and polyoxyethylated octyl phenol.
10. The vaccine composition of any of the preceding claims, wherein the composition is packed, sterilized, and in ready-to-inject form, and the composition is in unit dosage form containing the AGE antigen in an amount of 1 microgram to 100 milligrams.
11. The vaccine composition of any of the preceding claims, wherein the composition is in unit dosage form containing the AGE antigen in an amount of 10- 1000 micrograms.
12. The vaccine composition of any of the preceding claims, wherein the composition is packed, sterilized, and in ready-to-inject form,
the composition is in multidosage form containing 2-10 doses, and
each dosage contains the AGE antigen in an amount of 1 microgram to 100 milligrams.
13. The vaccine composition of any of the preceding claims, wherein each dosage contains the AGE antigen in an amount of 10-1000 micrograms.
1 . A method of treating atherosclerosis, comprising immunizing a human patient in need thereof against AGE-modified proteins.
15. The method of any of the preceding claims, wherein the immunizing comprises administering a vaccine comprising an AGE antigen.
16. The method of any of the preceding claims, wherein the vaccine comprises
(a) the AGE antigen,
(b) an adjuvant,
(c) a preservative, and
(d) optionally, an excipient.
17. A method of immunizing a human patient against AGE-modified proteins, comprising administering the vaccine composition of any of the preceding claims, in an amount effective to cause immunization against AGE-modified proteins.
18. A method of immunizing a human patient against AGE-modified proteins, comprising administering the vaccine composition of any of the preceding claims, in an amount effective to cause immunization against AGE-modified proteins.
19. The method of any of the preceding claims, wherein the vaccine composition is administered 2 to 10 times.
20. The method of any of the preceding claims, wherein the vaccine composition is administered 2 to 10 times over a time period of 1 week to 1 year.
21. The vaccine composition of any of the preceding claims, wherein the AGE antigen excludes AGE-modified albumin and AGE-modified collagen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470167P | 2011-03-31 | 2011-03-31 | |
US61/470,167 | 2011-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012135616A1 true WO2012135616A1 (en) | 2012-10-04 |
Family
ID=46931934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/031446 WO2012135616A1 (en) | 2011-03-31 | 2012-03-30 | Vaccination against advanced glycation end-products |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012135616A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
US9161810B2 (en) | 2008-05-23 | 2015-10-20 | Siwa Corporation | Methods, compositions and apparatuses for facilitating regeneration |
US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
WO2017222535A1 (en) * | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US10584180B2 (en) | 2014-09-19 | 2020-03-10 | Siwa Corporation | Anti-AGE antibodies for treating inflammation and auto-immune disorders |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
US11833202B2 (en) | 2016-02-19 | 2023-12-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
US11958900B2 (en) | 2017-04-14 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766590A (en) * | 1994-12-30 | 1998-06-16 | Alteon Inc. | Therapeutic methods and pharmaceutical compositions |
US5811075A (en) * | 1984-03-19 | 1998-09-22 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
US20080160506A1 (en) * | 2000-10-09 | 2008-07-03 | Yung-Hsiang Liu | Immunological analytical method and device for the determination of advanced glycosylation end products (AGEs) |
US20100028359A1 (en) * | 2008-05-09 | 2010-02-04 | Abbott Gmbh & Co. Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
-
2012
- 2012-03-30 WO PCT/US2012/031446 patent/WO2012135616A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811075A (en) * | 1984-03-19 | 1998-09-22 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
US5766590A (en) * | 1994-12-30 | 1998-06-16 | Alteon Inc. | Therapeutic methods and pharmaceutical compositions |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
US20080160506A1 (en) * | 2000-10-09 | 2008-07-03 | Yung-Hsiang Liu | Immunological analytical method and device for the determination of advanced glycosylation end products (AGEs) |
US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
US20100028359A1 (en) * | 2008-05-09 | 2010-02-04 | Abbott Gmbh & Co. Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11261241B2 (en) | 2008-05-23 | 2022-03-01 | Siwa Corporation | Methods, compositions and apparatuses for facilitating regeneration |
US9161810B2 (en) | 2008-05-23 | 2015-10-20 | Siwa Corporation | Methods, compositions and apparatuses for facilitating regeneration |
US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US10226531B2 (en) | 2010-09-27 | 2019-03-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US9320919B2 (en) | 2010-11-22 | 2016-04-26 | Siwa Corporation | Selective removal of cells having accumulated agents |
US10960234B2 (en) | 2010-11-22 | 2021-03-30 | Siwa Corporation | Selective removal of cells having accumulated agents |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
US10584180B2 (en) | 2014-09-19 | 2020-03-10 | Siwa Corporation | Anti-AGE antibodies for treating inflammation and auto-immune disorders |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US11873345B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Product and method for treating sarcopenia |
US11872269B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Method and composition for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US11833202B2 (en) | 2016-02-19 | 2023-12-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
WO2017222535A1 (en) * | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US20220160869A1 (en) * | 2016-06-23 | 2022-05-26 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US11213585B2 (en) | 2016-06-23 | 2022-01-04 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US11542324B2 (en) | 2017-04-13 | 2023-01-03 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US11958900B2 (en) | 2017-04-14 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012135616A1 (en) | Vaccination against advanced glycation end-products | |
US11872269B2 (en) | Method and composition for treating sarcopenia | |
JP6712304B2 (en) | GLA monotherapy for use in cancer treatment | |
Scheerlinck et al. | Systemic immune responses in sheep, induced by a novel nano-bead adjuvant | |
US11213585B2 (en) | Vaccines for use in treating various diseases and disorders | |
JP4164361B2 (en) | Vaccine with enhanced immune response and method for its preparation | |
US10925937B1 (en) | Vaccines for use in treating juvenile disorders associated with inflammation | |
JP2002535350A (en) | Non-invasive dermal vaccination | |
EP4143238A1 (en) | Methods of treating infections | |
Charoenvit et al. | CEL-1000—a peptide with adjuvant activity for Th1 immune responses | |
US20230381309A1 (en) | Methods of treating diffuse large b-cell lymphoma | |
WO2009052561A1 (en) | Compositions and methods for manipulating an immune response | |
Shimizu et al. | Lymphoid follicle antigen (Ag) delivery and enhanced rodent humoral immune responses mediated by Ag-containing PEGylated liposomes | |
Duryee et al. | Increased immunogenicity to P815 cells modified with malondialdehyde and acetaldehyde | |
CA2882553A1 (en) | Preparation for preventing or treating type i diabetes | |
Gruber | METHOD AND COMPOSITION FOR TREATING SARCOPENIA-Patent Information | |
Seiler et al. | BCG versus VCN: The antigenicity and the adjuvant effect of both compounds | |
WO2023056337A1 (en) | Tlr8 agonist for modulating immune response | |
WO2023056334A1 (en) | Tlr4 agonist for modulating immune response | |
Tye | downloaded from the King’s Research Portal at https://kclpure. kcl. ac. uk/portal | |
EP1165142A2 (en) | Lipid-based artificial particles inducing cell-mediated immunity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12764507 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12764507 Country of ref document: EP Kind code of ref document: A1 |